Microbot Medical Inc. (NASDAQ:MBOT) Given Consensus Recommendation of “Hold” by Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have earned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $6.3750.

Several equities analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a research report on Wednesday, August 19th. Loop Capital set a $4.00 target price on shares of Microbot Medical in a report on Wednesday, June 3rd. Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research report on Wednesday, July 8th.

Microbot Medical Stock Down 1.3%

Shares of MBOT stock opened at $1.48 on Friday. The stock has a 50-day simple moving average of $1.74 and a 200 day simple moving average of $2.04. The stock has a market capitalization of $99.41 million, a P/E ratio of -6.17 and a beta of 1.06. Microbot Medical has a fifty-two week low of $1.44 and a fifty-two week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. On average, sell-side analysts anticipate that Microbot Medical will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On Microbot Medical

Several large investors have recently modified their holdings of the stock. CIBC Bancorp USA Inc. acquired a new position in shares of Microbot Medical in the 3rd quarter worth $4,435,000. DNB Asset Management AS lifted its holdings in shares of Microbot Medical by 178.1% during the fourth quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock valued at $1,355,000 after purchasing an additional 433,869 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Microbot Medical by 14.3% during the third quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock valued at $7,148,000 after purchasing an additional 292,923 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Microbot Medical by 54.4% in the 4th quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 268,609 shares during the period. Finally, 683 Capital Management LLC acquired a new position in shares of Microbot Medical in the 4th quarter valued at $512,000. 16.30% of the stock is owned by institutional investors.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.